SecBot SecBot
PRESS-RELEASE ·Filed May 26, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor the webcasts for any strategic commentary on setmelanotide label expansion or pipeline progress, but this filing alone does not warrant a trading action.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$89.82
T+0 close · May 26, 2026 · via day close
Latest settled
+28.85%
T+60 · $115.73
Vs SPY
+26.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $89.82entry
  2. T+1 · 6mo ago +1.78%α +1.77% · $91.42
  3. T+5 · 6mo ago −2.17%α −3.25% · $87.87
  4. T+20 · 5mo ago +20.22%α +22.17% · $107.99
  5. T+60 · 3mo ago +28.85%α +26.12% · $115.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference (June 4) and Goldman Sachs 47th Annual Global Healthcare Conference (June 8). This is a routine investor relations event with no new financial data, clinical updates, or regulatory decisions disclosed.

Key Facts

  • CFO Hunter Smith to speak at Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 p.m. ET
  • CEO David Meeker to speak at Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 1:20 p.m. ET
  • Webcasts will be available on the company's investor relations page with replays for 30 days
  • No financial results, guidance, clinical data, or regulatory updates were provided in this release

Financial Impact

No financial impact, this is a routine conference participation announcement with no material financial data disclosed.

Risk Factors

  • No new clinical or financial data, stock may be range-bound until next catalyst

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3300998

Track record

26 reports on RYTM

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026